Myeloid Malignancies

Research in the Laboratory of Myeloid Malignancies, led by Dr. Christopher Hourigan, focuses on detection, prevention, and treatment of acute myeloid leukemia (AML).


Senior Investigator Research Interests

Research Interests

Acute myeloid leukemia (AML) is a rare, highly fatal, blood cancer. Although the majority of younger patients treated with chemotherapy will achieve an initial apparent “complete remission”, subsequent treatment with either further chemotherapy or allogeneic hematopoietic cell transplantation (alloHCT) cannot prevent subsequent death from leukemic relapse in many individuals. The outlook is often especially suboptimal for those diagnosed with AML but not eligible for this intensive therapy due to advanced age or medical co-morbidity. Recent advances in the scientific understanding of the genetic diversity of AML has led to the development of targeted therapies, but the optimal way to integrate such agents into a comprehensive approach for an individual AML patient has yet to be defined. The Myeloid Malignancies Section was established to investigate the“detection, prevention and treatment of AML relapse, in particular using non-transplantation immunotherapy”.  

Dr. Hourigan’s research focuses on three complementary approaches that are united by an overriding theme of performing translational research in order to find ways to detect, prevent and treat AML relapse. These efforts are strengthened by collaborations with a variety of clinical colleagues from leukemia and transplant centers from around the world.

The first research goal of Dr. Hourigan’s lab is to develop tools for the high sensitivity detection of residual AML after treatment that could help predict patients who may be at risk of relapse and whom may benefit from additional therapy.  Such tools may also be able to quantify the efficacy of therapeutic interventions, particularly those given in remission with the intent of preventing relapse.  This “measurable residual disease” (MRD) concept is the foundation for a personalized medicine approach to AML, now being tested in international trials. A second, and related, area of research undertaken by Dr. Hourigan’s lab involves the detection and monitoring of specific leukemia immune responses in patients, particularly before and after immunotherapy. New developments in immunotherapy and the powerful graft-versus-leukemia effect already observed after alloHCT all offer hope that AML is potentially susceptible to control by the immune system in the non-SCT setting. By analyzing the “immune health” of AML patients the team hopes to determine predictive biomarkers of the ability to respond to immunotherapy and to search for immune prognostic markers associated with successful long-term clinical outcomes.   Finally, while the first two research efforts are “bedside-to-bench” in nature, the third mission of the section is to translate insights from the laboratory back to the clinic, with several clinical trials of both high sensitivity diagnostics and immunotherapy for AML patients performed at the NIH clinical center.

The work carried out by Dr. Hourigan’s laboratory should help bring clinicians one step closer to developing personalized and effective treatment approaches for AML.



staff photo
Click the image to expand

Opening of the Myeloid Malignancies Clinic and PEARL15 Clinical Protocol

Opening of the Myeloid Malignancies Clinic and PEARL15 Clinical Protocol at NIH, July 2015.

Meet the Team


Christopher Hourigan, M.D., D.Phil.


Christopher Hourigan received both his medical degree and D. Phil. in Human Immunology from Oxford University. After residency training in medicine at Guy’s and St. Thomas’ Hospital in London and the Johns Hopkins Bayview Medical Center in Baltimore, he joined the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital where he was both a clinical fellow in medical oncology and a postdoctoral research fellow in the Immunology and Immunotherapy research program. He is ABIM board certified in Internal Medicine, Hematology and Medical Oncology. Dr. Hourigan came to the NHLBI in 2012. After almost three years as an Assistant Clinical Investigator, Dr Hourigan was appointed as an Investigator in March 2015.  Dr. Hourigan is a Fellow of the Royal College of Physicians, and the recipient of the NHLBI Directors Award, the NHLBI Orloff Award, the NIH Bench to Bedside Award, the NIH Directors Challenge Innovation Award, an American College of Physicians Early Career Physician Award, the American Society for Clinical Investigation (ASCI) Young Physician-Scientist Award and the Presidential Early Career Award for Scientists and Engineers (PECASE).


Georgia Andrew

Postbaccalaureate Fellow
2020 - 2022
Georgia Andrew is currently at Astrazeneca.

Chidera Nosiri

2019 - 2021
Chidera Nosiri is currently a Medical Student at Case Western Reserve.

Meghali Goswami, B.S.

Technical IRTA
2012 - 2020
Meghali Goswami, B.S. is currently a Ph.D. Graduate Student at George Washington University.

Jack Ghannam

2018 - 2020
Jack Ghannam is currently a MD-PhD Student at Harvard Medical School–MIT.

Bogdan Popescu

Postdoctoral Fellow
2018 - 2019
Bogdan Popescu is currently a Post-Doctoral Research Fellow (Catherine Smith MD) at Division of Hematology/Oncology, UCSF.

Haydar Celik

2019 - 2019
Haydar Celik is currently a Senior Director, Clinical and Regulatory Affairs at Goldbug Strategies LLC.

Hong Yuen Wong

Postdoctoral Fellow
2016 - 2018
Hong Yuen Wong is currently a Research Associate at Johns Hopkins School of Medicine.

Katie Lindblad

2016 - 2018
Katie Lindblad is currently a Ph.D. Student at Mt Sinai University, New York.

Karolyn Oetjen

Clinical Fellow
2016 - 2018
Karolyn Oetjen is currently a Instructor at Washington University School of Medicine in St Louis.

Catherine Lai

Staff Clinician
2015 - 2017
Catherine Lai is currently a Director of Leukemia at Georgetown Lombardi Cancer Center.

Sheenu Sheela

Special Volunteer/Clinical Fellow
2015 - 2017
Sheenu Sheela is currently a Clinical Fellow at Levine Cancer Institute.

Nestor Ramos, M.D.

Special Volunteer/Clinical Fellow
2015 - 2017
Nestor Ramos, M.D. is currently a Major and Attending Oncologist at US Army.

Gregory Roloff

2016 - 2017
Gregory Roloff is currently a Medical Student at University of Buffalo .

Sheida Hayati

Postdoctoral Fellow
2017 - 2017
Sheida Hayati is currently a Research Investigator at Bristol-Myers Squibb.

Christin "Blair" Destefano

Primary Mentor (NIH Special Volunteer)
2017 - 2017
Christin "Blair" Destefano is currently a Attending Physician, Hematological Malignancies at Walter Reed National Military Medical Center, Washington, DC.

Jingrong Tang, M.D., Ph.D.

2012 - 2016
Jingrong Tang, M.D., Ph.D. is currently a Biologist at NHLBI.

Mathew Mule

Postbaccalaureate IRTA
2014 - 2016
Mathew Mule is currently a M.D.-Ph.D. Student at UNC School of Medicine.

Aasheen Qadr

Summer Intern
2015 - 2015
Aasheen Qadr is currently a Undergraduate at University of Maryland.

Nirosha Perera

Summer Intern
2014 - 2014
Nirosha Perera is currently a Pre-Medical Undergraduate Student at Harvard University.

Vishal Ranpura, M.D.

Special Volunteer/ Clinical Fellow
2013 - 2014
Vishal Ranpura, M.D. is currently a Attending Oncologist at Southern California.

Katie McGowan

2013 - 2013
Katie McGowan is currently a Undergraduate Student at Georgetown University.